By Fineline Cube 
German pharmaceutical major Merck KGaA (ETR: MRK) is reportedly nearing the completion of its acquisition of US-based SpringWorks Therapeutics for USD 3.5 billion, according to the Wall Street Journal. SpringWorks’ stock price increased by 9.03% to USD 44.93 on Thursday afternoon following the announcement. Insiders indicate that the companies have agreed on a price close to USD 47 per share, with the deal expected to be finalized as early as next Monday if discussions proceed smoothly.
SpringWorks’ Portfolio and Performance
SpringWorks’ first drug, Ogsiveo (nirogacestat), an oral γ secretase inhibitor approved for desmoid tumors in the US, has been a significant contributor to the company’s revenue. In 2024, SpringWorks generated USD 191 million in revenues, with USD 172 million attributed to Ogsiveo. Earlier this year, the company also received US marketing approval for Gomekli (mirdametinib), an oral MEK inhibitor for the treatment of type 1 neurofibromatosis (NF1) and symptomatic plexiform neurofibromatosis (PN) that cannot be completely resected.-Fineline Info & Tech